Entero Therapeutics Appoints New CMO, Director
Ticker: GRDX · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $66,560 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-compensation
TL;DR
Entero Therapeutics brings on a new CMO and adds a director to the board.
AI Summary
Entero Therapeutics, Inc. announced on July 17, 2024, the appointment of Dr. Jonathan L. Cohen as Chief Medical Officer and the election of Ms. Sarah E. Empey to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, though specific dollar amounts for these arrangements were not detailed in this filing.
Why It Matters
Changes in key leadership roles like CMO and board composition can signal shifts in strategic direction and operational focus for a pharmaceutical company.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan L. Cohen (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Empey (person) — Elected to Board of Directors
- July 17, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan L. Cohen has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah E. Empey has been elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 17, 2024.
What other items are covered in this filing besides director and officer changes?
The filing also covers compensatory arrangements of certain officers.
What was Entero Therapeutics, Inc. formerly known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-07-23 16:05:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
- $66,560 — eed to reduce his annual base salary to $66,560, effective July 1, 2024. Other than thi
Filing Documents
- tm2419937d1_8k.htm (8-K) — 26KB
- 0001104659-24-081888.txt ( ) — 195KB
- fwbi-20240717.xsd (EX-101.SCH) — 3KB
- fwbi-20240717_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240717_pre.xml (EX-101.PRE) — 22KB
- tm2419937d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 17, 2024, the Board of Directors (the "Board") of Entero Therapeutics, Inc. (the "Company"), received a letter (the "Letter") from Dr. Jack Syage, the Company's Chief Scientific Officer, President and member of the Board, whereby he tendered his resignation from the role of Chief Scientific Officer of the Company, effective immediately. Dr. Syage will continue in his roles with the Company as its President and member of the Board. Dr. Syage resigned as Chief Scientific Officer in connection with certain cost reduction measures taken by the Company and not due to a disagreement with the Company's operations, policies or practices. In the Letter, Dr. Syage agreed to reduce his annual base salary to $66,560, effective July 1, 2024. Other than this change in annual base salary, Dr. Syage's compensation and employment terms, as set forth in his offer letter dated March 13, 2024, will not change as a result of the resignation from the officer position described above.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. July 23, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer